United States · FDA National Drug Code directory
RYSTIGGO
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50474-983_48d5f5c1-c45c-cb63-e063-6394a90a31c8
- Product NDC
- 50474-983
- Form
- INJECTION, SOLUTION
- Composition / generic term
- ROZANOLIXIZUMAB
- Labeler
- UCB, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240614
- Source listing expiry
- 20271231
Source-listed ingredients
- ROZANOLIXIZUMAB — 140 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, GLASS in 1 CARTON (50474-983-86) / 6 mL in 1 VIAL, GLASS · 50474-983-86
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →